Medtronic’s (MDT) Heart Devices Are Suddenly Outgrowing The Rest Of Med-Tech

insidermonkey.com · 2026-09-10

On September 1, Medtronic (NYSE:MDT) reported fiscal 2027 first-quarter results that blew past its own guidance, with revenue of $9.8 billion and organic growth of 13.7%.

TickrTrends take: Medtronic's acceleration in heart devices represents a meaningful shift in its growth trajectory within a business segment that historically drives significant revenue and margins. Given TickrTrends' current assessment of the company as fairly valued, investors focused on valuation metrics should monitor whether this outperformance in cardiac products can sustain and translate into earnings growth that justifies the current price. A sustained acceleration in this division could alter the fair value calculation if it demonstrates that the company's growth profile is stronger than previously reflected in the market consensus.

Read the full story at insidermonkey.com →